Real‐world results with IgPro20 for hypo‐ or agammaglobulinemia in Japan

BACKGROUND: Subcutaneous immunoglobulin is one of the standard treatments for hypogammaglobulinemia in primary immunodeficiencies (PID) worldwide. In Japan, IgPro20 (Hizentra(®); l‐proline‐stabilized 20% human subcutaneous immunoglobulin) is approved for agammaglobulinemia or hypogammaglobulinemia d...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Kohsuke, Ishii, Tomonori, Nonoyama, Shigeaki, Yasumi, Takahiro, Kanegane, Hirokazu, Fukushima, Taku, Matsumaru, Masayuki, Akasaki, Tetsushi, Usui, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099597/
https://www.ncbi.nlm.nih.gov/pubmed/36151913
http://dx.doi.org/10.1111/ped.15362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099597/
https://www.ncbi.nlm.nih.gov/pubmed/36151913
http://dx.doi.org/10.1111/ped.15362

Ejemplares similares